RELB antibody - 100 µg
Host : Rabbit
Clonality: Polyclonal
Clone:
Isotype: IgG
Immunogen: v-rel reticuloendotheliosis viral oncogene homolog B
Purity: ≥95% as determined by SDS-PAGE
Form: Liquid
Molecular weight: 62 kDa
Uniprot: Q01201
Gene id: 5971
Background: NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo-or heterodimeric complex formed by the Rel-like domain-containing proteins RELA
p65, RELB, NFKB1
p105, NFKB1
p50, REL and NFKB2
p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor(I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases(IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA
p65 or REL. Stimulates promoter activity in the presence of NFKB2
p49. As a member of the NUPR1
RELB
IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL
BMAL1 heterodimer in a CRY1
CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2
p52.
Field of research: Epigenetics, Signal Transduction, Metabolism, Cardiovascular, Immunology
Storage conditions: PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months(Avoid repeated freeze
thaw cycles.)
Applications: ELISA, IF, IHC, IP, WB
Dilution: WB: 1:500-1:5000; IP: 1:200-1:1000; IHC: 1:20-1:200; IF: 1:10-1:100
Target: RELB
Purification: Immunogen affinity purified
Reactivity: Human
![]()
Clonality: Polyclonal
Clone:
Isotype: IgG
Immunogen: v-rel reticuloendotheliosis viral oncogene homolog B
Purity: ≥95% as determined by SDS-PAGE
Form: Liquid
Molecular weight: 62 kDa
Uniprot: Q01201
Gene id: 5971
Background: NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo-or heterodimeric complex formed by the Rel-like domain-containing proteins RELA
p65, RELB, NFKB1
p105, NFKB1
p50, REL and NFKB2
p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor(I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases(IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA
p65 or REL. Stimulates promoter activity in the presence of NFKB2
p49. As a member of the NUPR1
RELB
IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL
BMAL1 heterodimer in a CRY1
CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2
p52.
Field of research: Epigenetics, Signal Transduction, Metabolism, Cardiovascular, Immunology
Storage conditions: PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months(Avoid repeated freeze
thaw cycles.)
Applications: ELISA, IF, IHC, IP, WB
Dilution: WB: 1:500-1:5000; IP: 1:200-1:1000; IHC: 1:20-1:200; IF: 1:10-1:100
Target: RELB
Purification: Immunogen affinity purified
Reactivity: Human